Female Sexual Dysfunction: Causes, Hormones, and Treatment Options

Female sexual dysfunction (FSD) is one of the most prevalent yet underdiagnosed conditions in women's health. Studies estimate that 30–40% of women experience some form of sexual dysfunction at some point in their lives, yet fewer than 25% ever discuss it with a healthcare provider. Understanding the hormonal, psychological, and physiological roots of FSD is the first step toward effective treatment.

Types of Female Sexual Dysfunction

The DSM-5 and international sexual medicine guidelines recognize several overlapping categories:

• Hypoactive Sexual Desire Disorder (HSDD): Persistent, distressing absence of sexual thoughts, fantasies, or desire. The most common form of FSD, affecting approximately 10% of premenopausal and up to 30% of postmenopausal women.
• Female Sexual Arousal Disorder (FSAD): Difficulty achieving or maintaining sufficient genital lubrication and engorgement during sexual activity.
• Female Orgasmic Disorder (FOD): Significant delay, infrequency, or absence of orgasm despite adequate stimulation.
• Genito-Pelvic Pain/Penetration Disorder (GPPPD): Persistent pain during intercourse or penetration, encompassing conditions formerly known as vaginismus and dyspareunia.

The Hormonal Roots of Female Sexual Dysfunction

Hormones are among the most powerful regulators of female sexual function. Disruptions across several key hormones commonly contribute to FSD:

Testosterone

Although often considered a "male hormone," testosterone plays a critical role in female sexual desire, arousal, and satisfaction. Levels naturally decline with age, dropping by approximately 50% between the ages of 20 and 40. Surgical menopause (removal of ovaries) causes an abrupt 50–60% drop in circulating testosterone.

Low testosterone in women presents as decreased libido, difficulty with arousal, reduced genital sensitivity, and diminished orgasm intensity. Low-dose testosterone therapy — though not yet FDA-approved specifically for FSD — is supported by multiple randomized trials showing significant improvements in desire and sexual satisfaction in postmenopausal women.

Estrogen

Estrogen maintains vaginal tissue health, lubrication, and blood flow. As estrogen declines during perimenopause and menopause, the result is genitourinary syndrome of menopause (GSM): vaginal dryness, thinning (atrophy), reduced lubrication, and pain during intercourse. Local estrogen therapy (vaginal estrogen cream, ring, or suppository) effectively treats GSM with minimal systemic absorption and is recommended even for women who cannot use systemic HRT.

Progesterone

Progesterone has a complex relationship with sexual function. While some studies suggest progesterone may dampen libido at high levels (explaining reduced desire during the luteal phase), progesterone deficiency in perimenopause is associated with sleep disturbance, anxiety, and mood disruption — all of which indirectly impair sexual function.

Thyroid Hormones

Both hypothyroidism and hyperthyroidism impair sexual function. Hypothyroidism reduces libido, causes vaginal dryness, and diminishes arousal. Thyroid optimization is often an overlooked step in addressing FSD — women with unexplained sexual complaints should always have thyroid function tested.

Non-Hormonal Contributors to FSD

Sexual dysfunction in women is rarely purely hormonal. Important contributing factors include:

• Antidepressants (SSRIs/SNRIs): One of the most common iatrogenic causes of FSD; up to 70% of women on SSRIs report some form of sexual side effect.
• Oral contraceptives: Can lower free testosterone and reduce SHBG balance, decreasing libido in some women.
• Relationship factors: Partner dynamics, communication, and emotional intimacy profoundly influence desire and satisfaction.
• Trauma history: Sexual trauma is strongly linked to arousal disorders, pain disorders, and anorgasmia.
• Chronic illness: Diabetes, cardiovascular disease, and autoimmune conditions all impair sexual response through vascular, neurological, and fatigue-related mechanisms.

FDA-Approved Treatments for Female Sexual Dysfunction

Flibanserin (Addyi)

The first FDA-approved medication for premenopausal HSDD. Works by modulating serotonin and dopamine neurotransmission in the brain's reward pathway. Taken daily, it modestly but significantly increases desire and satisfying sexual events in clinical trials. It cannot be combined with alcohol and is not effective for postmenopausal women.

Bremelanotide (Vyleesi)

A melanocortin receptor agonist injected subcutaneously 45 minutes before anticipated sexual activity. Approved for premenopausal HSDD. Bremelanotide works through central nervous system pathways distinct from hormonal mechanisms — making it useful even when hormones are normal. Common side effects include transient nausea and flushing.

Local Estrogen and DHEA (Intrarosa)

For women with GPPPD due to GSM, vaginal DHEA (prasterone) converts locally to both estrogen and testosterone, improving tissue health, lubrication, and pain during intercourse without significant systemic absorption.

The Role of PT-141 (Bremelanotide) in Telehealth

PT-141 — the research peptide form of bremelanotide — is increasingly prescribed through telehealth platforms for women experiencing low desire or arousal difficulties. Unlike hormonal treatments, PT-141 acts centrally on melanocortin receptors, producing desire-enhancing effects within 30–60 minutes of administration. It is particularly valuable for women in whom hormonal approaches have been insufficient or are contraindicated.

Frequently Asked Questions

Is female sexual dysfunction a normal part of aging?

While hormonal changes with age do affect sexual function, significant, distressing dysfunction is not simply an inevitable consequence of aging — it is a treatable medical condition. Women of all ages deserve effective, personalized care for sexual health concerns.

Can I address HSDD without hormones?

Yes. Flibanserin and bremelanotide (PT-141) are both non-hormonal options approved for HSDD. Mindfulness-based sex therapy and cognitive-behavioral therapy also have strong evidence for improving desire and satisfaction, particularly when psychological factors are prominent.

Does testosterone therapy for women have significant side effects?

When prescribed at physiological doses, testosterone therapy in women is generally well tolerated. Potential side effects — including mild acne, increased hair growth, or voice changes — are dose-dependent and typically resolve with dose adjustment. Supraphysiological doses used in bodybuilding are not medically appropriate or safe for women.